The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study

Basit Öğe Kaydı
dc.authorid0000-0003-1513-6149
dc.contributor.authorKamaşak, Tülay
dc.contributor.authorSerdaroğlu, Esra
dc.contributor.authorYılmaz, Özlem
dc.contributor.authorAydın Kılıç, Betül
dc.contributor.authorGönüllü Polat, Burçin
dc.contributor.authorErdoğan, Irmak
dc.contributor.authorYücel Şen, A. Derda
dc.contributor.authorÖzen, Nalan
dc.contributor.authorDurgut, Betül Diler
dc.contributor.authorYıldız, Nihal
dc.contributor.authorÖzkan Kart, Pınar
dc.contributor.authorDilber, Beril
dc.contributor.authorAcar Arslan, Elif
dc.contributor.authorŞahin, Sevim
dc.contributor.authorTopçu, Yasemin
dc.contributor.authorGençpınar, Pınar
dc.contributor.authorSerin, ?Hepsen Mine
dc.contributor.authorHız, Semra A.
dc.contributor.authorÇarman, Kürşat Bora
dc.contributor.authorOlgaç Dündar, Nihal
dc.contributor.authorOkuyaz, Çetin
dc.contributor.authorAydın, Kürşad
dc.contributor.authorSerdaroğlu, Ayşe
dc.contributor.authorTekgül, Hasan
dc.contributor.authorCansu, Ali
dc.date.accessioned2022-07-04T08:37:13Z
dc.date.available2022-07-04T08:37:13Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractObjective: To evaluate the effectiveness and tolerability of clobazam therapy in the pediatric population in terms of seizure semiology, epileptic syndromes, and etiological subgroups. Methods: A retrospective cohort study was conducted consisting of 1710 epileptic children from eight centers in seven geographic regions of Turkey. The initial efficacy of clobazam therapy was evaluated after three months of treatment. The long-term effectiveness of the drug, overall seizure outcomes, and overall therapeutic outcomes were evaluated during 12 months of therapy. Results: Analysis of initial efficacy after the first three months of clobazam therapy showed that 320 (18.7 %) patients were seizure-free, 683 (39.9 %) had > 50 % seizure reductions, and 297 (17.4 %) had < 50 % seizure reductions. A positive response (seizure-free and >50 % seizure reduction) was determined for focal-onset (62.3 %) seizures, epileptic spasms (61.5 %), and generalized onset seisures (57.4). The highest positive response rate among the epileptıc syndromes was for self-limited epilepsy with centrotemporal spikes (SeLECTS). The highest negative response rate was for developmental and/or epileptic encephalopathies (DEEs). Magnetic resonance imaging (MRI) revealed a structural etiological diagnosis in 25.8 % of the cohort. A higher positive response rate was observed at MRI in patients with sequelae lesions than in those with congenital lesions. The seizure recurrence rate was higher in the patient group with epilepsy wıth genetic and metabolic causes, in individuals with more than one seizure type, and in those using three or more antiseizure drugs. Conclusions: This cohort study provides additional evidence that clobazam is an effective and well-tolerable drug with a high seizure-free rate (18.7 %), a significant seizure reduction rate (57.3 %), and with excellent overall therapeutic outcomes with a low seizure relapse rate and considerable reversible benefits in the pediatric population.
dc.identifier.citationKamaşak, T., Serdaroğlu, E., Yılmaz, Ö., Aydın Kılıç, B., Gönüllü Polat, B., Erdoğan, I. ... Cansu, A. (2022). The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study. Epilepsy Research, 184. http://doi.org/10.1016/j.eplepsyres.2022.106963
dc.identifier.doi10.1016/j.eplepsyres.2022.106963
dc.identifier.issn0920-1211
dc.identifier.issn1872-6844
dc.identifier.pmid35749975
dc.identifier.scopus2-s2.0-85132518462
dc.identifier.scopusqualityQ2
dc.identifier.urihttp://doi.org/10.1016/j.eplepsyres.2022.106963
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9557
dc.identifier.volume184
dc.identifier.wos000822813500002en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAydın Kılıç, Betül
dc.institutionauthorTopçu, Yasemin
dc.institutionauthorAydın, Kürşad
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofEpilepsy Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectChildhood Epilepsy
dc.subjectClobazam
dc.subjectLennox-Gastaut Syndrome
dc.subjectReversible Effect of Clobazam
dc.subjectWest Syndrome
dc.titleThe effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Kilic-Betül-2022.pdf
Boyut:
474.17 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu